Drug Database
RA

rabies vaccine

✓ Approved

Serum Institute of India Pvt. Ltd. · 疫苗 · 疫苗

什么是 rabies vaccine?

rabies vaccine 是一种疫苗,由Serum Institute of India Pvt. Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intradermal Injection、Intramuscular (IM) Injection。

药物档案

公司Serum Institute of India Pvt. Ltd.
药物类别疫苗, 大分子
给药途径Injectable (Others), Intradermal Injection, Intramuscular (IM) Injection
状态Approved

治疗适应症

rabies vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsRabies✓ Approved

相关研究文献

PubMedOne health (Amsterdam, Netherlands)2026-11-20

Determinants of rabies pre-exposure prophylaxis vaccination willingness among pet hospital staff in Guiyang, China: A cross-sectional study.

Deng Yuanyuan Y, Ding Jiangfeng J, Tian Li L, Hu Yuandong Y

Rabies pre-exposure prophylaxis (PrEP) is recommended for high-risk occupational groups, yet vaccination coverage remains low among pet hospital staff in China. This study aimed to assess PrEP acceptance and associated factors in this population. A cross-sectional survey was conducted from September to December 2024 using multistage sampling. Data on demographics, PrEP knowledge, and vaccination willingness were collected from 229 staff across Guiyang's pet hospitals. Logistic regression analyses identified key determinants. A total of 241 questionnaires were collected, with 229 valid responses (valid response rate: 95.0%). The willingness rate for PrEP was 68.1% (156/229), while the actual PrEP vaccination rate was only 9.8% (17/174 among those who had received any rabies vaccine). Univariate chi-square tests showed that vaccination willingness differed significantly by monthly income (P < 0.001), prior PrEP vaccination status (P = 0.003), and belief about whether rabies vaccine can be given before exposure (P < 0.001). Multivariate logistic regression revealed that participants with a monthly income of ≥ ¥6000 (OR = 19.35, 95% CI = 2.05-182.25, P = 0.010), those who believed that rabies vaccination before injury was not possible (OR = 7.38, 95% CI = 1.77-30.82, P = 0.006), and those who were uncertain (OR = 11.45, 95% CI = 2.00-65.66, P = 0.006) were significantly less willing to receive PrEP. Willingness to recommend PrEP was lower among those who believed that vaccination before injury was not permissible (OR = 2.94, 95% CI = 1.22-7.08, P = 0.016). Economic barriers and knowledge gaps-especially the misconception "no exposure, no vaccination"-are major obstacles to PrEP uptake among pet hospital staff.

PMID 43061505
阅读全文 →
PubMedJournal of global health2026-11-20

Future vaccine priorities in Cambodia: preparedness for emerging infectious diseases.

Puth Sao S, Loeurng Vandara V

Cambodia has achieved substantial progress in immunisation over the past two decades, culminating in one of Southeast Asia's most successful COVID-19 vaccination campaigns. However, the epidemiological landscape is rapidly changing. Climate change, environmental degradation, urbanisation, increasing regional mobility, and intensified human-animal interactions are increasing the risk of emerging infectious diseases, placing Cambodia at the frontline of future epidemic and pandemic threats. Although national vaccine policy has traditionally focused on childhood immunisation, preparedness for emerging infectious diseases requires a broader strategy that integrates pathogen surveillance, genomic monitoring, regulatory readiness, rapid vaccine platforms, and One Health collaboration. Here, we highlight the need for Cambodia to transition from a vaccine delivery agenda toward a broader vaccine preparedness agenda. We propose a national framework centred around surveillance-informed vaccine prioritisation, strengthened laboratory and genomic capacity, resilient vaccine delivery systems, sustainable financing, and regional partnerships. Such an approach could enhance Cambodia's preparedness for pathogens including H5N1, dengue, Japanese encephalitis, rabies, and future Disease X scenarios, while strengthening its contribution to regional health security.

PMID 43061856
阅读全文 →
PubMedAntibody therapeutics2026-11-20

The barrier effect of high-affinity IgM neutralizing antibodies provides enhanced blockage against rabies virus transport and infection.

Chen Shuo S, Wang Hongye H, Li Bingxiang B, Guo Xinwen X et al.

Antibody-mediated protection plays a crucial role in post-exposure prophylaxis against rabies infection, while engineered antibodies with novel functional mechanisms offer enhanced preventive efficacy. In this study, we investigated the in vitro and in vivo activities as well as the protective efficacy of CR4008 antibodies with different conformational structures. We demonstrated that under passive immunization with antibodies of equivalent neutralizing efficacy, IgM antibodies exhibited superior protection against viral challenge compared with other antibodies. The underlying mechanism involves antibody barriers along the sarcolemma by IgM antibodies, which effectively inhibits viral transport in the infectious microenvironment within muscle tissues. Following high-affinity binding and neutralizing, barrier antibodies prevent the virus from retrogradely spreading to the central nervous system and prevent rabies development. Our study suggests that, in addition to neutralizing activity, effective inhibition of viral spread caused by the unique distribution of Immunoglobulin M (IgM) antibodies in exposed tissues is critical and valuable for passive immunization against rabies infection.

PMID 43060989
阅读全文 →
PubMedmedRxiv : the preprint server for health sciences2026-11-20

Ontology-Based SEA-CDM Integration for Vaccine Clinical Trials: Query, Similarity, and Design Recommendation.

Zhu Jiadong J, Yeh Feng-Yu Leo FL, Zheng Jie J, He Yongqun Oliver YO

gov provides valuable information for vaccine research, but fragmented data structures and inconsistent vaccine naming complicate systematic cross-trial analysis. The Study-Experiment-Assay Common Data Model (SEA-CDM) provides a standardized structure for biomedical study data, while biomedical ontologies supply semantic relationships among concepts. We extracted 9,147 vaccine-related study records from the Aggregate Analysis of ClinicalTrials.gov (AACT) database, mapped their records into SEA-CDM, and linked vaccine products and reported adverse events (AEs) to the Vaccine Ontology (VO) and Ontology of Adverse Events (OAE), respectively. Building on the existing Ontology-based SEA Network (OSEAN), we organized the integrated data into relational tables and a Neo4j knowledge graph while retaining links to original registrations. We evaluated three applications to assess semantic trial retrieval, context-aware AE ranking and trial similarity, and trial design recommendation. First, VO-based query expansion retrieved 41 candidate RNA vaccine trials compared with 16 using exact VO identifier matching. Second, a context-aware AE ranking model incorporating SEA-CDM features and VO-derived vaccine families improved recall@10 from 0.317 to 0.383 over a frequency-based baseline. TransE and CompGCN embeddings achieved Hits@10 of 0.950 and 0.946, respectively, for retrieving trials sharing the same VO identifier within disease-specific candidate sets. Third, an ontology-based clinical trial design recommendation model was developed using several machine learning methods under leave-one-Material-out evaluation across 23 vaccine classes, although performance varied across classes. These findings demonstrate how structural and semantic integration can support multiple clinical trial analyses using vaccine studies as a case study. This framework provides a foundation for extending ontology-supported data integration and analysis to other clinical research domains.

PMID 43059852
阅读全文 →
PubMedmedRxiv : the preprint server for health sciences2026-11-20

Psychological inoculation protects young women in South Africa against HIV prevention misinformation: Evidence from a randomised controlled trial.

Maughan-Brown Brendan B, Pandey Divya D, Bokolo Simamkele S, Egbe Teniola I TI et al.

Misinformation decreases public confidence in health technologies and willingness to use them. Psychological inoculation, or "prebunking", exposes people to misleading claims before they spread widely and refutes the claims and embedded persuasion tactics. Evidence on its effectiveness for HIV-related misinformation, particularly in sub-Saharan Africa and among young women (a population highly vulnerable to HIV), is limited. We conducted a randomised controlled trial (July to October 2025) among 2,163 women aged 18-29 years recruited online in South Africa. Participants were randomly assigned to view two short TikTok-style inoculation videos addressing common myths about an HIV vaccine, or attention-matched control videos on nutrition and diabetes. All participants then viewed multiple false claims presented as social media posts. The primary outcome was intention to receive an HIV vaccine if available (1-10 scale), assessed immediately post-intervention and at three-week follow-up. Secondary outcomes included likelihood of recommending the vaccine; and perceived credibility, emotional impact, and shareability of misinformation claims. We used linear regression models to estimate intervention effects. Misinformation exposure reduced vaccine intentions by 0.63 points in the control group, while intentions increased by 0.30 points in the intervention group. Controlling for covariates and baseline intentions, post-exposure vaccine intentions were 0.92 points higher in the intervention group (95% CI 0.78, 1.06; p<0.01), a 12% relative increase. Intervention participants were also more likely to recommend the vaccine (+0.74; 95% CI 0.61, 0.88; p<0.01). Inoculation reduced perceived credibility, emotional distress, and sharing intentions across all false claims. Effects persisted at three-week follow-up (vaccine intentions: +0.97; 95% CI 0.78, 1.17; p<0.01). Brief, scalable psychological inoculation delivered via social-media-style videos protected young women's HIV vaccine intentions, with effects generalising to novel claims and persisting over three weeks. Prebunking campaigns may safeguard public confidence in other new HIV prevention technologies like lenacapavir.

PMID 43060761
阅读全文 →
PubMedBiometrics2026-11-20

Vaccine sieve analysis of deep sequencing data using competing risks Cox regression with failure type subject to misclassification.

Peng James J, Juraska Michal M, Shaw Pamela A PA, Gilbert Peter B PB

Understanding how vaccines perform against different pathogen genotypes is crucial for developing effective prevention strategies, particularly for highly genetically diverse pathogens like HIV. Sieve analysis is a statistical framework used to determine whether a vaccine selectively prevents infection by certain genotypes while allowing breakthrough of other genotypes that evade immune responses. Traditionally, these analyses are conducted with a single sequence available per individual acquiring the pathogen. However, modern sequencing technology can provide detailed characterization of intra-individual viral diversity by capturing up to hundreds of pathogen sequences per person. In this work, we introduce methodology that extends sieve analysis to account for intra-individual viral diversity. Our approach estimates vaccine efficacy against viral populations with at least a small threshold of vaccine-mismatched mutations. To account for differential resolution of information from differing sequence counts per person, we use competing risks Cox regression with modeled causes of failure and propose an empirical Bayes approach for the classification model. Simulation studies demonstrate that our approach reduces bias, provides nominal confidence interval coverage, and improves statistical power compared to conventional methods. We apply our method to the HVTN 705 Imbokodo trial, which assessed the efficacy of a heterologous vaccine regimen in preventing HIV-1 infection.

PMID 43055100
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多rabies vaccine